Teva Pharmaceuticals informed the Tel Aviv Stock Exchange, Tuesday morning, that it has received certification from the United States Food and Drug Adminstration (FDA) that it meet production regulations.

Teva was warned by the FDA in January about shortcomings in its oral solid dosage facility in Jerusalem. Last night the company announced that it had received word from the FDA that it passed an inspection in June.

The price of Teva stock rose .65 percent in the first half hour of trading at the Tel Aviv Stock Exchange to 140.10.